Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Luxembourg Institute Of Health is active in the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 1 pending office action. This matter is assigned to 1 distinct examiner and 1 distinct art unit, reflecting a centralized prosecution effort for the institute's current filings. This concentration is common for research institutions that are pursuing patent protection for a specific medical or biological discovery within a single technical field.
The busiest examiner for the portfolio is JADHAO, SAMADHAN JAISING, who is responsible for 1 busiest_examiner_pending action. Since there is only 1 pending office action, the institute's current success in obtaining patent protection depends on the specific examination process led by this individual examiner. Practitioners should be prepared to address the specific technical concerns of this examiner, as there are no other pending actions to provide a wider view of the patent office's stance on the institute's technology. The focus on 1 distinct art unit indicates that the prosecution is being conducted within a single specialized technical division.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JADHAO, SAMADHAN JAISING | 1 | 46.2% | +47.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258676 | PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PROTOPARVOVIRUS AND AN ANTIVIRAL BENZIMIDAZOLE AND USES THEREOF FOR TREATING CANCER | JADHAO, SAMADHAN JAISING | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18258676 | PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PROTOPARVOVIRUS AND AN ANTIVIRAL BENZIMIDAZOLE AND USES THEREOF FOR TREATING CANCER | JADHAO, SAMADHAN JAISING | 1672 | §103 | Non-Final OA | — | Pending | Jun 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLuxembourg Institute Of Health has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Samadhan Jaising Jadhao has the most, with 1 of Luxembourg Institute Of Health's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
